Synergistic Efficacy in Human Ovarian Cancer Cells by Histone Deacetylase Inhibitor TSA and Proteasome Inhibitor PS-341

Abstract

Histone deacetylase inhibitors and proteasome inhibitor are all emerging as new classes of anticancer agents. We chose TSA and PS-341 to identify whether they have a synergistic efficacy on human ovarian cancer cells. After incubated with 500 nM TSA or/and 40 nM PS-341, we found that combined groups resulted in a striking increase of apoptosis and G2/M blocking rates, no matter in A2780, cisplatin-sensitive ovarian cancer cell line OV2008 or its resistant variant C13*. This demonstrated that TSA interacted synergistically with PS-341, which raised the possibility that combined the two drugs may represent a novel strategy in ovarian cancer.

Keywords: :

• Histone deacetylase inhibitor
• Proteasome inhibitor
• Ovarian cancer
• p21

ACKNOWLEDGMENTS

The authors received grant from the National Science Foundation of China (30770914, 30801224, 30770913, 30700895); Major Innovation Medicine program (2009ZX09103-738; 2009ZX09103-739;2009ZX09103-740); and “973” Program (2009CB521808).